ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.
